Medtronic received the first U.S. Food and Drug Administration (FDA) approval for an implantable cardioverter defibrillator (ICD) system for use with magnetic resonance imaging (MRI) scans. The Medtronic Evera MRI SureScan ICD System is approved for MRI scans on any part of the body without positioning restrictions, which means that patients who depend on life-saving ICDs also now have access to MRI scans if and when they need them. The newly approved system, which will be commercially available in September 2015, includes the Evera MRI ICD and Sprint Quattro Secure MRI SureScan DF4 leads, which must be used together to be considered MR-conditional.
Texas Heart Institute (THI) announced that it has received a prestigious American Heart Association grant alongside Rice University. The three-year, $750,000 grant will allow THI and Rice researchers to study and test soft, flexible fibers made of carbon nanotubes. The fibers’ ability to bridge electrical gaps in tissue is a groundbreaking discovery and offers hope to the millions of people affected by cardiac arrhythmias.
Startup cardiovascular device manufacturer Valtech Cardio Ltd. announced it has received CE Marking for its Cardioband mitral reconstruction system (Cardioband), a proprietary, implantable mitral reconstruction device with a transfemoral, transseptal delivery system for mitral valve repair.
Cardiac PET/CT represents a major advancement in cardiovascular diagnostics, offering significant clinical and ...
Vital Images Inc. recently introduced the VioSuite Image Management and Vitality Solutions Business Intelligence product families, providing healthcare administrators with a robust set of tools to improve system-wide image access and image data analytics. VioSuite and Vitality Solutions, as well as the company’s flagship products VitreaAdvanced and VitreaView software, were showcased at the 9th annual Health Information and Management Systems Society (HIMSS) Asia Pacific Conference and Exhibition.
September 14, 2015 — Healthcare providers can assess a patient’s risk of sudden cardiac death (SCD) following a ...
New Haven Pharmaceuticals Inc. announced U.S. Food and Drug Administration (FDA) approval of Durlaza (aspirin) 24-hour extended-release capsules for the secondary prevention of stroke and acute cardiac events, including myocardial infarction.
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
Zevacor Molecular (Zevacor), manufacturer and distributor of positron emission tomography (PET) and single photon emission computed tomography (SPECT) radiopharmaceuticals, announced the arrival of a 70 MeV Cyclotron at its new production facility in Noblesville, Indiana.
Westinghouse Electric Company and NorthStar Medical Radioisotopes announced a memorandum of understanding to explore producing medical radioisotopes from the core of commercial nuclear reactors, and methods of global distribution. The exploration involves generating the most widely used radioisotope in medical diagnostic imaging by treating an isotope of the chemical element molybdenum rather than enriched uranium.
September, 11, 2015 – Japanese medical vendor Nipro Corp. signed a definitive agreement to acquire Infraredx Inc., maker ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
The cardiovascular service line, whether existing within the confines of an acute-care environment or outpatient setting ...
For any cardiology department looking to upgrade or replace its cardiovascular information system (CVIS), the main ...
Two key requirements for today’s cardiovascular information systems (CVIS) are solid integrations with both enterprise ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Sunshine Heart Inc. announced commencement of a new study examining the impact of the C-Pulse system on pulmonary circulation and right heart related to pulmonary hypertension and heart failure.
AliveCor Inc. announced significant milestones related to patients with atrial fibrillation (AFib) using the AliveCor Mobile ECG. Since receiving the first U.S. Food and Drug Administration (FDA) clearance for the AF Detector, an algorithm to detect atrial fibrillation in an ECG (electrocardiogram), 30 percent of AliveCor patients have received an AFib detection.
The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical regimen of optimal medical treatment (OMT), the present standard of care for functional mitral regurgitation (FMR).
September 14, 2015
